Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists

被引：13

作者：

Dzierba, CD ^{[1
]}

Takvorian, AG ^{[1
]}

Rafalski, M ^{[1
]}

Kasireddy-Polam, P ^{[1
]}

Wong, H ^{[1
]}

Molski, TF ^{[1
]}

Zhang, G ^{[1
]}

Li, YW ^{[1
]}

Lelas, S ^{[1
]}

Peng, Y ^{[1
]}

McElroy, JF ^{[1
]}

Zaczek, RC ^{[1
]}

Taub, RA ^{[1
]}

Combs, AP ^{[1
]}

Gilligan, PJ ^{[1
]}

Trainor, GL ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 23期

关键词：

D O I：

10.1021/jm049737f

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Corticotropin releasing factor (CRF) is the primary regulator of the hypothalamus-pituitary-adrenal (HPA) axis, coordinating the endocrine, behavioral, and autonomic responses to stress. It has been postulated that small molecules that can antagonize the binding of CRF, to its receptor may serve as a treatment for anxiety-related and/or affective disorders. Members within a series of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones, exemplified by compound 2 (IC50 = 0.70 nM), were found to be very potent antagonists of CRF1. Compound 8w showed high CRF1 receptor binding affinity and was examined further in vivo. The compound was efficacious in a defensive withdrawal model of anxiety in rats and had a long half-life and reasonable oral bioavailability in dog pharmacokinetic studies.

引用

页码：5783 / 5790

页数：8

共 50 条

[1] Synthesis, structure-activity relationships and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor 1 antagonists.
Dzierba, CD
Takvorian, AG
Rafalski, M
Kasireddy-Polam, P
Combs, AP
Zhang, G
Marshall, A
Mattson, GK
Molski, TF
Lodge, NJ
Ren, SX
Zhao, B
Wong, H
Li, YW
Ward, KA
Lelas, S
McElroy, JF
Taub, RA
Zaczek, RC
Trainor, GL
Gilligan, PJ
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U40 - U40
[2] HETEROCYCLES STRUCTURALLY INFLUENCED BY A SIDE-CHAIN .7. 3-PHENACYLIDENE-3,4-DIHYDRO-1H-PYRIDO[2,3-B]PYRAZIN-2-ONES AND 2-PHENACYLIDENE-1,2-DIHYDRO-4H-PYRIDO[2,3-B]PYRAZIN-3-ONES
SEKI, T
SAKATA, H
IWANAMI, Y
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1995, 32 (01) : 347 - 348
[3] Synthesis and structure-activity relationships of pyrido[3,2-b] pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists
Dzierba, Carolyn D.
Sielecki, Thais M.
Arvanitis, Argyrios G.
Galka, Amy
Johnson, Tricia L.
Takvorian, Amy G.
Rafalski, Maria
Kasireddy-Polam, Padmaja
Vig, Shikha
Dasgupta, Bireshwar
Zhang, Ge
Molski, Thaddeus F.
Wong, Harvey
Zaczek, Robert C.
Lodge, Nicholas J.
Combs, Andrew P.
Gilligan, Paul J.
Trainor, George L.
Bronson, Joanne J.
Macor, John E.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (15) : 4986 - 4989
[4] UNAMBIGUOUSLY CONFIRMED STRUCTURE OF 2-PHENACYLIDENE-1,2-DIHYDRO-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE AND 3-PHENACYLIDENE-3,4-DIHYDRO-1H-PYRIDO[2,3-B] PYRAZIN-2-ONE
SEKI, T
SAKATA, H
IWANAMI, Y
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1995, 32 (02) : 703 - 704
[5] Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists
Lowe, RF
Nelson, J
Dang, TN
Crowe, PD
Pahuja, A
McCarthy, JR
Grigoriadis, DE
Conlon, P
Saunders, J
Chen, C
Szabo, T
Chen, TK
Bozigian, H
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) : 1540 - 1549
[6] Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists
Hartz, Richard A.
Ahuja, Vijay T.
Schmitz, William D.
Molski, Thaddeus F.
Mattson, Gail K.
Lodge, Nicholas J.
Bronson, Joanne J.
Macor, John E.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 1890 - 1894
[7] Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: Structure-activity relationships and computational modeling
Dzierba, Carolyn D.
Tebben, Andrew J.
Wilde, Richard G.
Takvorian, Amy G.
Rafalski, Maria
Kasireddy-Polam, Padmaja
Klaczkiewicz, John D.
Pechulis, Anthony D.
Davis, Amy L.
Sweet, Mark P.
Woo, Alex M.
Yang, Zhicai
Ebeltoft, Sarah M.
Molski, Thaddeus F.
Zhang, Ge
Zaczek, Robert C.
Trainor, George L.
Combs, Andrew P.
Gilligan, Paul J.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (09) : 2269 - 2272
[8] Synthesis, Structure-Activity Relationships, and In Vivo Evaluation of N3-Phenylpyrazinones as Novel Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists
Hartz, Richard A.
Ahuja, Vijay T.
Arvanitis, Argyrios G.
Rafalski, Maria
Yue, Eddy W.
Denhart, Derek J.
Schmitz, William D.
Ditta, Jonathan L.
Deskus, Jeffrey A.
Brenner, Allison B.
Hobbs, Frank W.
Payne, Joseph
Lelas, Snjezana
Li, Yu-Wen
Molski, Thaddeus F.
Mattson, Gail K.
Peng, Yong
Wong, Harvey
Grace, James E.
Lentz, Kimberley A.
Qian-Cutrone, Jingfang
Zhuo, Xiaoliang
Shu, Yue-Zhong
Lodge, Nicholas J.
Zaczek, Robert
Combs, Andrew P.
Olson, Richard E.
Bronson, Joanne J.
Mattson, Ronald J.
Macor, John E.
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (14) : 4173 - 4191
[9] Design, synthesis and structure-activity relationships of 5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists
Takeda, Kunitoshi
Terauchi, Taro
Hashizume, Minako
Shikata, Kohdoh
Taguchi, Ryota
Murata-Tai, Kaoru
Fujisawa, Masae
Takahashi, Yoshinori
Shin, Kogyoku
Ino, Mitsuhiro
Shibata, Hisashi
Yonaga, Masahiro
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
[10] Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists
Takeda, Kunitoshi
Terauchi, Taro
Hashizume, Minako
Shikata, Kohdoh
Taguchi, Ryota
Murata-Tai, Kaoru
Fujisawa, Masae
Takahashi, Yoshinori
Shin, Kogyoku
Ino, Mitsuhiro
Shibata, Hisashi
Yonaga, Masahiro
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (22) : 6559 - 6578

← 1 2 3 4 5 →